Published Date: 13 Mar 2023
OSA itself predicted the incidence of MACCE in non-obese patients.
Read Full NewsA recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.
The newly approved inhibitor is for patients who previously received another drug of the same class.
1.
Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975
2.
Researchers Challenge USPSTF's Lung Cancer Screening Criteria
3.
Prostate cancer Q&A: Improving detection and reducing overtreatment
4.
Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted
5.
How 7,000 steps a day could help reduce your risk of cancer
1.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
2.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
3.
How is Digital Innovation Revolutionizing Gynecologic Oncology Treatment and Patient Engagement?
4.
Comprehensive Applications in Oncology and Quality Improvement
5.
Apheresis vs. IVMP in Cancer Treatment: A Tale of Two Titans
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation